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Abstract
Background: Many obese will eventually develop diabetes and 
cardiovascular disease. The metabolic syndrome is a cluster of risk 
factor for these diseases, and low-grade inflammation has been 
linked to all three conditions.
Thesis aims: To investigate if high-sensitivity C-reactive protein can 
be a useful tool in risk assessment for the development of the 
metabolic syndrome in abdominally obese patients. Also, to explore 
what recent studies have found regarding the significance of the 
abdominal adipose tissue is in this syndrome.
Material and method: The thesis is a litterature study. The medical 
database PubMed was used to search for relevant articles.
Results & conclusion: Increasing waist circumference is 
independently associated with hs-CRP, indicating that abdominal 
obesity is associated with low-grade inflammation. Hs-CRP 
correlates with individual factors in the metabolic syndrome, but it 
does not seem to add any information to the formal criteria. It can not 
predict the presence of the metabolic syndrome.
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1.0 Introduction & thesis central question
There is an obesity pandemic among us which the health care 
systems are not ready for. The World Health Organization estimates 
that nearly 1,5 billion adults worldwide are overweight (BMI ≥ 25), 
and of those 500 million people are clinically obese (BMI ≥ 30). 
Overweight and obesity are now the 5th leading risk for global deaths 
[1]. Many clinically obese will eventually develop diabetes and most 
of them will die of cardiovascular disease, the number one cause of 
death globally [2]. 
The four conventional cardiovascular risk factors are still smoking, 
diabetes/obesity, hypertension and hypercholesterolemia, but the 
abscence of these does not fully protect from the development of 
cardiovascular disease. At least 10-20% of cardiovascular events 
occur in individuals without traditional risk factors [3], and many 
patients with cardiovascular events have cholesterol levels below 
standard interventional thresholds [4]. This has raised the question of 
whether or not new tools are needed in cardiovascular risk 
assessment. 
Hs-CRP is the most extensively studied inflammatory biomarker in 
cardiovascular disease. In the last 10-15 years it has emerged as a 
promising indicator of cardiovascular disease risk idependent of other 
risk factors. The metabolic syndrome is a clustering of risk factors for 
diabetes and cardiovascular disease, and abdominal obesity is a 
central feature in this syndrome. The syndrome is recognized as both 
a proinflammatory and prothrombotic state, but the cause of this is 
not yet fully understood [41] [42, 43]. I wanted to know if hs-CRP 
could be used in risk assessment at an early stage, when type 2 
diabetes and cardiovascular disease has not been established. If so, 
the test could be a tool in the prevention of morbidity and mortality 
associated with these diseases.
                                                                                                                                  
The central question of this thesis is: 
«Can high-sensitivity C-reactive protein be a useful tool in risk 
assessment for the development of the metabolic syndrome, and 
what is the significance of the abdominal adipose tissue in this 
syndrome?»
This is a thesis of limited size, and the field of adipose tissue 
pathophysiology is vast and ever-expanding. I have chosen to focus 
on the inflammatory aspect of the abdominal adipose tissue in the 
metabolic syndrome, i.e. its production of cytokines, and the 
relationship to C-reactive protein production. 
                                                                                                                                  
2.0 Method
This thesis is a litterature study in which I have used the medical 
database PubMed to search for relevant articles. I used the following 
key words alone or in combinations to search for information on 
topics of interest:
inflammation, CRP, C-reactive protein, high-sensitivity C-reactive 
protein, hs-CRP, cytokines, adiopokines, atherosclerosis, 
cardiovascular disease, CVD, type 2 diabetes, insulin resistance, 
obesity, abdominal obesity, central obesity, metabolic syndrome, risk, 
prognostic.
I also used other sources of information for background research, 
such as internationally acclaimed textbooks and websites like 
uptodate.com and Norsk Elektronisk Legehåndbok 
(legehandboka.no), all known for researched based information for 
clinicians. 
There are several definitions of the metabolic syndrome. This has 
created confusion among clinicans and researchers, making it 
difficult to directly compare data from studies where different 
definitions has been used. However, the definitions are quite similar 
so in this paper I have chosen to compare papers regardless of 
which definition has been used, as long as waist circumference/
abdominal obesity was one of the factors studied. I have also chosen 
to use studies where BMI was one of the criteria where this was 
appropriate. I also use central obesity, abdominal obesity and 
increased waist circumference interchangeably, as does most 
definitions of the metabolic syndrome.
                                                                                                                                  
3.0 Results
3.1 Basic concepts 
 3.1.1 C-reactive protein - a short introduction
C-reactive protein is a well-known unspecific marker of inflammation 
and tissue damage. Is is part of a family of molecules called acute 
phase reactants made by the liver cells. The role of CRP is not fully 
understood, but we know that it plays a role in host defence and in 
clearance of apoptotic and necrotic cells. Common analysis 
indications in clinical use today are suspected bacterial infections, 
differentiating between viral and bacterial infections, following 
disease processes and detecting postoperative complications [5]. 
3.1.2 Common disorders of glucose metabolism related to 
obesity
Insulin resistance is a state where a subnormal glucose response is 
seen for a given concentration of insulin. The central feature is 
hyperglycemia, i.e when insulin becomes less effective at lowering 
blood glucose levels. However, insulin have several other functions 
and the effects depend on the cells involved. The most important 
tissues affected by insulin resistance are muscle, fat and liver. As an 
example, in an insulin resistent patient the adipocytes may reduce 
their uptake of circulating lipids and increase mobilization of stored 
lipids, resulting in elevated triglyceride levels in the blood [6].
When risk factors for type 2 diabetes are clustered with risk factors 
for cardiovascular disease, we call it the metabolic syndrome, also 
called insulin resistance syndrome or syndrome X [7] [8]. The details 
of the metabolic syndrome will be further discussed in the next 
section of this thesis. 
                                                                                                                                  
Type 2 diabetes is a metabolic disease characterised by chronic 
hyperglycemia with varying degrees of insulin resistance and/or 
relative insulin deficiency. 90% of patients with diabetes have type 2 
diabetes and many are unaware that they have the disease. Several 
studies have demonstrated a strong association between both insulin 
resistance & the metabolic syndrome and risk for development of 
type 2 diabetes [9] [10] [11] [12]. The most important risk factors for 
type 2 diabetes are obesity (particularly abdominal/central obesity) 
and physical inactivity [13]. The long term effects of type 2 diabetes 
are the same as for type 1 diabetes: Micro- and macrovascular 
disease, neuropathy and nephropathy. The overall risk of dying is 
doubled in patients with diabetes compared to non-diabetics [14]. 
Studies has also shown that the relative risk for fatal coronary heart 
disease in women with type 2 diabetes is 50% higher then in men 
with the disease [15]. 3,2 million people die each year from 
complications associated with diabetes. 75-80% of them die of 
cardiovascular disease [13, 14]. 
3.1.3 An overview of cardiovascular disease (CVD)
Cardiovascular disease is defined as disease relating to or of the 
heart and blood vessels. The pathological process of atherosclerosis 
is responsible for most cases of cardiovascular disease. There are 
four major areas of cardiovascular disease seen from a diagnostic 
standpoint [16]: 
* Coronary heart disease (angina pectoris, myocardial infarction, 
heart failure and coronary death). Accounts for about 1/3-1/2 of the 
total cases of CVD.
* Cerebrovascular disease (stroke and transient ischemic attack)
* Peripheral artery disease (intermittent claudication)
*  Aortic atherosclerosis & thoracic and abdominal aneurisms 
                                                                                                                                  
Hypertension and dyslipidemia are well established risk factors, as is 
diabetes. Lifestyle factors like smoking, obesity, diet and exercise 
can also have a great impact on cardiovascular disease risk [16].
3.2 Low-grade inflammation & inflammatory mediators
3.2.1 C-reactive protein - an acute phase reactant
Inflammation is a protective mechanism which organisms depend 
upon for survival. Without it damaged tissue can not heal and 
infections can not be fought. It is not a disease, but a non-specific 
response that is beneficial to the organism. 
Inflammation and tissue injury is followed by the acute phase 
respons, a group of physioloigcal processes that occur soon after the 
onset of trauma, infection, inflammatory processes and other non-
physiological states. The acute phase response comprises several 
factors like fever and increased vascular permeability. It also includes 
a change in the concentration of acute phase reactants in the serum. 
C-reactive protein is an well-known unspecific marker of inflammation 
and tissue damage, although its functions has not yet been fully 
established. Its rapid response shows that it is a part of the innate 
immune system. It is one of many known acute phase reactants 
produced by the hepatocytes. 
Acute phase reactants are proteins whose serum concentrations 
increase or decrease at lest 25% during inflammatory states. 
Changes in the levels of these proteins are influenced by 
inflammatory molecules called cytokines, such as interleukin-6 (IL-6), 
tumor necrosis factor-alpha (TNF-alpha). During inflammatory 
processes cytokines are mainly produced by immune cells like 
                                                                                                                                  
monocytes and macrophages, but can also be produced by other 
cells, such at fat cells. Despite being called acute phase reactants 
they not only accompany acute inflammatory conditions, but also 
chronic inflammatory states [17]. 
3.2.2 Low-grade inflammation and metabolic stress
Inflammation and its significant role in chronic diseases has been 
extensively researched and is becoming widely accepted. In 
February 2004, it was featured as the cover story in the popular 
magazine Time, named «The Secret Killer». Chronic low-grade 
inflammation has been shown to play a key role in cardiovascular 
disease; throughout the atherosclerotic process from endothelial 
dysfunction to plaque rupture and thrombosis. The state of low-grade 
inflammation, also called para-inflammation or subclinical 
inflammation is, unfortunately, not very well defined. The signs of 
acute inflammation are missing here and the acute-phase response 
is only minor. It seems that the purpose of low-grade inflammation is 
to restore homeostasis in times of metabolic stress, and not to fight 
infection or clear necrotic cells as is the case with acute 
inflammation. This appears to be the basis for low-grade 
inflammation as seen in obesity, diabetes and cardiovascular disease 
[18] [19]. 
3.2.3 C-reactive protein - its characteristics and current uses in 
clinical practice and research
C-reactive protein is an acute phase protein of the pentraxin family, 
shaped as an annular pentameric disc. It was discovered in the 
1930s and got its name from its ability to bind to the C-
polysaccharide in the capsule of the pneumococcus bacteria [20]. It 
is synthesized in the liver by hepatocytes in response to inflammatory 
                                                                                                                                  
processes. It is up-regulated by cytokines, interleukin-6 being the 
chief stimulator of CRP production [21]. In healthy individuals the 
levels of CRP are seldom above 5 mg/L, with medians values 
ranging from 0,9 mg/L - 2,05 mg/L in different studies [5, 22]. High 
plasma concentrations are seen 6-12 hours after the initiation of a 
disease process, and it may increase several hundred-fold. It has a 
half-life of 15-25 hours, so its concentration falls fast as the healing 
progresses. Higher values are seen in diseases characterized by cell 
necrosis, and values above 40 mg/L may suggest bacterial infection 
[5]. It is a stable molecule and can easily be measured at any 
physicians office with a simple blood test. In general practice C-
reactive protein is commonly used to differentiate between bacterial 
and viral infection, but also to follow disease progression. In addition, 
in hospital settings it is often used to detect postoperative 
complications [5]. 
With new and improved antibodies available it is possible to measure 
concentrations of CRP with greater accuracy, specifically in the lower 
range. This analysis is called high-sensitivity CRP or micro-CRP, and 
is a sensitive marker for low-grade inflammation. It can measure 
serum concentrations down to 0,05-0,1 mg/L. It has been used in 
research for at least 10-15 years, but is not in common clinical use as 
of today. In 2003 the Centers for Disease Control and Prevention 
(CDC) and the American Heart Association (AHA) recommended 
patient stratification into three groups in cardiovascular disease risk 
assessment: low risk (hs-CRP< 1mg/L), intermediate risk (hs-CRP 
1-3 mg/L) and high risk (hs-CRP> 3 g/L) [23]. They concluded that 
hs-CRP was the analyte of choice to identify patients for primary 
prevention of cardiovascular disease. They did not recommend 
widespread use of hs-CRP for screening for cardiovascular disease 
risk. Moderate level of evidence (level C) resulted in the test being 
labeled «optional». They found that hs-CRP measurements 
appeared to be best employed to detect cardiovascular disease risk 
in patients with intermediate risk, i.e. with 10-20% risk of coronary 
heart disease over 10 years. These are patients without known CVD 
                                                                                                                                  
but who may be at higher absolute risk than estimated by major risk 
factors. The reaserch group concluded that hs-CRP could be used to 
adjust risk for CVD in these patients [23].
As a result, traditional cardiovascular disease risk score algorithms 
like the Framingham Risk Score are now being challenged by new 
risk-prediction models that incorporate hs-CRP. The Reynolds Risk 
Score is one such model [57]. In addition to the traditional risk factors 
it also includes hs-CRP and genetic risk. Studies have shown that it 
improves risk classification and the accuracy for total risk prediction, 
particularly for those classified as intermediate risk by usual 
algorithms [58] [59] [60].
Since CRP is an unspecific inflammatory marker, single 
measurements can be hard to interpret. As a result, a low level has 
more predictive value than a high one. A slight increase in CRP 
concentration needs to be confirmed by new blood samples. Several 
measurements should be taken in these cases, preferably at least 
three weeks apart, in order to be able to interpret the results and 
assess cardiovascular disease risk [5] [24]. 
Hs-CRP has been shown to predict the development of type 2 
diabetes and cardiovascular disease independently of established 
risk factors, and these studies has added to the growing body of 
evidence of low grade inflammation in the pathogenesis of type 2 
diabetes and cardiovascular disease [25] [4] [26] [37].
3.2.4 Obesity and adipose tissue-derived inflammatory 
mediators
The World Health Organization estimates that nearly 1,5 billion adults 
worldwide are overweight (BMI ≥ 25), and of those 500 million people 
are clinically obese (BMI ≥ 30). Overweight and obesity are now the 
                                                                                                                                  
5th leading risk for global deaths [1]. The close relationship between 
abdominal obesity, metabolic disturbances and cardiovascular 
disease has been apparent for clinicians throughout the ages. We 
now know that adipose tissue is not just a storage facility for fatty 
acids. It is an active endocrine organ, producing bioactive proteins 
named adipokines (or adipocytokines - adipose tissue-derived 
cytokines) [27, 28]. 
One of the most widely known is the hormone leptin (from the greek 
leptos, meaning thin), which was discovered in the mid 1990´s. It is 
almost exclusively secretet by adipocytes. It is a signal that reduces 
appetite, and for that reason it became the subject of intense 
research as many hoped it held the key to a cure for obesity [29]. 
The level of leptin circulating in the body is directly proportional to the 
total amount of body fat. As a result obese people have high levels of 
leptin. 
Other adipokines include interleukin-6, adiponectin, resistin, adipsin, 
tumor necrosis factor-alpha, plasminogen activator-inhibitor-1 and 
many more. This is a relatively new area of research, so there may 
be more discovered in the years to come. Also, some of the 
adipokines are produced by other cells as well as by adipocytes. The 
adipokines are involved in a multitude of processes like inflammation, 
insulin resistance, lipid metabolism, blood pressure, macrophage 
infiltration, fibrinolysis, food intake, fat mass regulation and more 
[30]. 
3.2.5 Adipokine levels in adipose tissue dysfunction
Obesity and adipose tissue has been shown to be associated with 
low-grade inflammation [31], and it is also strongly associated with 
inflammation and increased CRP-levels in obese, but healthy, people 
or people with subclinical disease [32][33]. The levels of plasma 
adipokines rise as adipose tissue/adipocytes increases in volume, 
                                                                                                                                  
except for adiponectin which decreases (reduced synthesis of 
adiponectin is seen in obesity, insulin resistance, metabolic 
syndrome and type 2 diabetes [34] [35]). There seems to be a shift 
toward proinflammatory adipokine dominance as adipcytes become 
enlarged [36]. In other words, there is an up-regulation/
hypersecretion of pro-inflammatory adipokines, and a decreased 
production adiponectin (an anti-inflammatory adipokine only 
produced in adipose tissue) [30] when fat tissue expands. The 
explanation for this has been suggested to be that as adipocytes 
becomes hypertophic, hypoxia may occur (due to hypoperfusion) 
inducing cellular stress [37]. This stimulates the expression of 
inflammatory genes and activates immune cells. There is an increase 
in macrophage infiltration in the increasing adipose tissues [38] [39], 
and both macrophages and adipocytes secrete cytokines. 
3.2.6 Adipose tissue-induced production of CRP 
Two of the first cytokines/adipokines to be associated with low-grade 
inflammation were interleukin-6 and tumor necrosis factor-alpha, and 
these have been shown to be up-regulated in obese patients [28]. 
Studies has shown that levels of CRP are significantly related to 
levels of IL-6 and TNF-apha [40]. Interleukin-6 is, as mentioned 
earlier, the chief stimulator of CRP production. Abdominal adipose 
tissue, with its increased production of cytokines from both immune 
cells and adipocytes, is drained directly to the portal circulation. It 
could be that this direct route to the liver, where CRP is produced, is 
partly responsible for the increased production of CRP in abdominally 
obese people [30]. Weight loss has shown to significantly decrease 
CRP levels in obese subjects  [41][42], which could support the 
theory that the adipose tissue is actively involved in the low-grade 
inflammatory state seen in abdominally obese people. 
                                                                                                                                  
3.3 The metabolic syndrome - a risk factor cluster
3.3.1 Confusing definitions and guidelines
As mentioned earlier, the metabolic syndrome is a cluster of many 
important and established risk factors for cardiovascular disease and 
type 2 diabetes. The concept later defined as the metabolic 
syndrome was first suggested by Reaven in 1988 [43], and several 
different definitions have been in use since it was first defined by 
WHO in 1998. Many are still in use, as there is no universal 
definition. There has also been much debate in the medical 
establishment about this fact and of whether or not it  is a real 
syndrome [44]. Following are some of the most widely used 
definitions:
The International Diabetes Federation definition, updated in 
2005/2006, states that:
«... for a person to be defined as having the metabolic syndrome 
they must have:
Central obesity (defined as waist circumference ≥ 94cm for Europid 
men and ≥ 80cm for Europid women, with ethnicity specific values for 
other groups). If BMI is > 30, central obesity can be assumed and 
waist circumference does not need to be measured.
plus any two of the following four factors:
* Raised TG level: ≥ 150 mg/dL (1.7 mmol/L), or specific treatment 
for this lipid abnormality 
* Reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L*) in males and 
< 50 mg/dL (1.29 mmol/L*) in females, or specific treatment for this 
lipid abnormality 
                                                                                                                                  
* Raised blood pressure: systolic BP ≥ 130 or diastolic BP ≥ 85 mm 
Hg, or treatment of previously diagnosed hypertension 
* Raised fasting plasma glucose (FPG) ≥ 100 mg/dL (5.6 mmol/L), or 
previously diagnosed type 2 diabetes
If above 5.6 mmol/L or 100 mg/dL, OGTT is strongly recommended 
but is not necessary to define presence of the syndrome. » [45]
The IDF concensus group of 2006 highlighted several parameters 
they thought should be included in research studies to «help 
determine the predictive powers of these extra criteria for CVD and/
or diabetes.» Among the areas mentioned for further study was the 
proinflammatory state - with elevated hs-CRP, elevated inflammatory 
cytokines (eg TNF-alpha and IL-6) and decreased adiponectin 
plasma levels. The prothrombotic state was another important area 
for further study according to the group [45].
In 2009, several major organizations, like the International Diabetes 
Federation and the American Heart Association, met in an attempt to 
unify the many different criteria used [44]. The resulting statement 
gave us new criteria for the metabolic syndrome with no obligatory 
components, and three out of five abnormal criteria qualify for the 
syndrome. The diagnostic criteria in this definition are: 
* Elevated waist circumference: Poulation- and country-specific 
definitions
* Elevated triglycerides: ≥ 150 mg/dL (1.7 mmol/L). Drug treatment 
for elevated triglycerides is another indicator.
* Reduced HDL-C: < 40 mg/dL (1.0 mmol/L) in males; < 50 mg/dL 
(1.3 mmol/L) in females. Drug treatment for reduced HDL-C is an 
alternate indicator.
* Elevated blodd pressure: Systolic ≥ 130 mm Hg and/pr diastolic ≥ 
85 mm Hg. Antihypertensive drug treatment in a patient with a 
history of hypertension is an alternate indicator.
                                                                                                                                  
* Elevated fasting blood glucose: ≥ 100 mg/dL. Drug treatment of 
elevated glucose is an alternate indicator. (Most patients with type 2 
diabetes mellitus will have the metabolic syndrome by the proposed 
criteria) [44].
The group ended their statement by saying: «... further studies 
exploring the relation of waist circumference thresholds to metabolic 
risk and cardiovascular outcomes in different populations  are 
encouraged, and we continue to recommend the use of waist 
measurement as a useful screening tool in many primary care 
situations.» 
Although the International Diabetes Federation was part of the 2009 
statement above, they still use their own definition from 2006 on their 
web page and in their publications [46]. This illustrates that there is 
still no universal definition. However, the when two commonly used 
criteria were compared, the definitions overlapped in 93% of of the 
subjects in determining the presence or absence of the syndrome 
[47].
3.3.2 The relationship between hs-CRP and the components of 
the metabolic syndrome
Increased levels of CRP has been found in obese people, and 
patients with metabolic syndrome have been found to have what the 
authors judged to be high-risk levels [48] [49]. Also, increasing 
number of components correlates with increasing CRP-levels [50] 
[48]. As the metabolic syndrome has several components, it could be 
that hs-CRP elevation is related to just one or some of these 
components. Several studies have been done to investigate the 
relationships between hs-CRP and the different components of the 
metabolic syndrome. 
                                                                                                                                  
A cross sectional study on nondiabetic subjects done by Yudkin et al. 
showed that levels of CRP were related to all measures of obesity. 
CRP-levels were also related to insulin resistance, blood pressure, 
HDL, and triglycerides and markers of endothelial dysfunction. The 
authors concluded that these research data suggested that adipose 
tissue is an important determinant of low-grade chronic inflammation, 
and that chronic low-grade inflammation may induce insulin 
resistance and endothelial dysfuction. They also stated that this 
could be a possible link between insulin resistance and endothelial 
dysfunction and obesity & cardiovascular disease [40]. 
A Tunisian case control study concluded that waist circumference 
was an significant independent predictor of elevated CRP levels in 
both men and women with the metablic syndrome [51]. Also, HDL-C 
was another significant predictor of elevated CRP levels in women 
only. 
A cross sectional study from Israel found that hs-CRP correlated 
significactly with all the components of the syndrome in both men 
and women, but the highest correlation was between waist 
circumference and hs-CRP [52]. From this the authors concluded 
that waist circumference is the component of the syndrome that most 
influences the low-grade inflammatory response. They also made the 
point that, according to their findings, also overweight and obese 
individuals without the syndrome were at an increased risk for 
cardiovascular disease.  
A German population-based study (using BMI and not waist 
circumference), concluded that there was a positive and statistically 
significant trend in levels of CRP with increasing numbers of 
components of the metabolic syndrome in their population 
(P<0.0001). The age-adjusted geometric means of CRP 
concentrations in subjects grouped according to the presence of 0-1, 
2-3 and ≥ 4 features of the metabolic syndrome were 1.11, 1.27, and 
2.16 mg/L, respectively. There was also a statistically significant 
                                                                                                                                  
crude correlation between CRP and triclygerides (R=0,19), BMI 
(R=0,32) and glucose (R=0,11) [53].
3.3.3 Can hs-CRP predict the presence of the metabolic 
syndrome?
Researchers have proposed adding hs-CRP as a clincal criterion for 
the metabolic syndrome [54]. The reasons given for this was that it 
has been shown to be a consistent prognosticator of cardiovascular 
and diabetes risk, and is practical in clinical settings.
A cross-sectional screening study done in the Netherlands evaluated 
the use of hs-CRP to discriminate between centrally obese people 
with and without the syndrome [55]. They concluded that hs-CRP 
has limited capacity to predict the precence of the metabolic 
syndrome in people with central obesity. With a cut-off point for hs-
CRP at 1.0 mg/L the sensitivity was 82%, the specificity 24%, the 
positive predictive value 38%, and the negative predictive value 71%. 
With a cut-off point at 3.0 mg/L the sensitivity was 37%, the 
specificity 72%, the positive predictive value 42% and negative 
predictive value 67%. The median hs-CRP levels were significantly 
higher in people with abdominal obesity with the metabolic syndrome 
than without it. As the numbers of components of the syndrome 
increased, so did the median hs-CRP levels. Only waist 
circumference and triglyceride levels showed a significant 
independent association with hs-CRP. They concluded that the 
degree of central obesity seemed to be the main determinant of 
increased hs-CRP levels. The levels of hs-CRP were higher in 
centrally obese people with the syndrome than those without it, but it 
could not be used to diagnose centrally obese people with the 
metabolic syndrome in this study. 
An Italian population based cohort, with healthy middled-aged 
subject without any components of the metabolic syndrome at 
                                                                                                                                  
baseline, found that higher baseline CRP values indicated increased 
risk of developing the syndrome, independently of weight gain. They 
concluded that the optimal cut-off point of baseline CRP values was 
2.1 mg/L, with 86% sensitivity and 75% specificity in detecting the 
syndrome [56]. 
                                                                                                                                  
4.0 Discussion
4.1 Is adipose tissue dysregulation the key to low-
grade inflammation in abdominal obesity?
Several studies shows that there seems to be a close relationship 
between increased amounts of abdominal/visceral fat, metabolic 
disturbances and cardiovascular disease. This is an already 
established connection. Both patients and physicians know this. The 
question is why? A lot of research data supports that obesity is 
associated with inflammatory changes in the body, and that these 
changes are accompanied with increased levels of C-reactive 
protein. These levels appear to become higher as the abdominal fat 
mass increases. Waist circumference seems to be the only 
component that has been independently associated with hs-CRP in a 
number of studies. This tells us that the theory of fat tissue 
dysregulation is a plausibel one, and the data seems to support it. 
However, this area of research is still new and the picture is perhaps 
not complete. It is very likely that new adipokines will continue to be 
discovered, and with that new connections and functions come to 
light. Interleukin-6 is produced by other cells and not adipocyte-
specific (like adiponectin), so no conclusions can be drawn until more 
research is done. 
4.2 Hs-CRP - does it add information beyond the 
metabolic syndrome criteria? 
Hs-CRP has many positive attributes. It is inexpesive, non-invasive,  
does not require fasting and is widely available to name a few. The 
question is, what can the test tell us that the criteria can not? The 
increased risk for diabetes and cardiovascular disease is a given, 
since the definition is a cluster of risk factors for these diseases. The 
                                                                                                                                  
linear increase in hs-CRP with increasing numbers of components of 
the metabolic syndrome is therefore not unexpected. 
Most of the factors that have been found to correlate with hs-CRP 
are easy to measure in family/general practice, like abdominal 
obesity, elevated blood pressure, low LDL and elevated triglycerides 
and fasting glucose. Hs-CRP does not seem to add any information 
to the formal criteria here. Hs-CRP also seems to be related to 
components of the metabolic syndrome that are not as easy to 
evaluate in family/general practice, like insulin resistance and 
impaired fibrinolysis. We know that insulin resistance is a key part of 
the syndrome, and since there is currently no validated test for 
measuring insulin resistance in a clinical setting, this should be 
further investigated. 
The presence of low-grade inflammation indicated by an elevated hs-
CRP level in abdominally obese patients with or without the 
syndrome indicates that these patients could be at an increased risk 
for diabetes and cardiovascular disease, and should so be subject to 
early interventions such as lifestyle change. But the presence of 
abdominal obesity in itself tells us that lifestyle changes should be 
made. This is nothing new. If the patient fulfill more of the syndrome 
criteria, these should be treated like they would in any other patient. 
The research data shows that hs-CRP could possibly add some 
prognostic information, but how to interpret this information without 
formal guidelines and reference values for this syndrome is a 
problem. If the hs-CRP values are slightly higher than normal it could 
indicate increased risk, but it could also mean that the CRP 
concentration is returning to normal after an infection or after tissue 
damage. To establish this it is important that the test is repeated to 
validate the finding. 
                                                                                                                                  
5.0 Conclusion
Many years may pass from the development of insulin resistance to 
clinical manifestations of diabetes and cardiovascular disease 
become apparent. Given the high prevalence of the metabolic 
syndrome, it is essential that patients with the metabolic syndrome 
are identified so that the development of diabetes and cardiovascular 
disease can be prevented. The different definitions in use make this 
a challenge, but since they are quite similar it is not an impossible 
task. A measuring tape, a sphygmomanometer, a stethoscope and a 
venous blood sample can make all the difference in the world to the 
patient involved. 
Whether or not we should add hs-CRP to the list of blood tests is as 
of now a clinical jugdement for the physician to make, as there are no 
formal guidelines regarding the metabolic syndrome. Hs-CRP does 
not appear to be a useful diagnostic tool since it has not been shown 
to reliably predict the precence of the metabolic syndrome in people 
with abdominal obesity. However, hs-CRP levels appear to become 
higher as the abdominal fat mass increases, and waist circumference 
seems to be the only component that has been independently 
associated with hs-CRP. This tells us that the theory of fat tissue 
dysregulation is a plausibel one, but since so many known, and 
probably unknown, factors interact it is not possible to draw any 
conclusions without further study.
The problem of how to interpret the findings seems to be the most 
important point against using the hs-CRP in screening or risk 
assessment today, as there are no guidelines or verified reference 
areas for the metabolic syndrome. More research is needed before 
hs-CRP can be considered as a tool to asess the risk for the 
development of the metabolic syndrome in apparently healthy 
abdominally obese people.
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